Upgraded 23andME to $1.28

We are upgrading 23andMe’s stock price:

• Increased adoption of direct-to-consumer (DTC) genetic testing: The market for DTC genetic testing is projected to grow in the coming years, which could benefit 23andMe.
• Expansion into new markets or partnerships: Entering new markets or forming strategic partnerships could boost revenue and investor confidence.
• Breakthroughs in gene editing or personalized medicine: Advancements in these areas could significantly impact 23andMe’s future potential.
• Artificial Manipulation of stock: We believe stock price is being artificially manipulated to make it more attractive to larger firms for a takeover

Our near term price target is $2.28